Paradigm Biopharmaceuticals (CHIA:PAR) - Aandelenkoers, Nieuws & Analyse

PAR Overzicht aandelen

Paradigm Biopharmaceuticals Limited houdt zich bezig met onderzoek naar en ontwikkeling van therapeutische producten voor menselijk gebruik in Australië. Meer informatie

PAR fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Heeft minder dan 1 jaar cash runway

Heeft een omzet van minder dan 1 miljoen USD ( A$0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen betekenisvolle marktkapitalisatie ( A$114M )

+ 2 meer risico's

Paradigm Biopharmaceuticals Limited Concurrenten

Cynata Therapeutics

ASX:CYP

AU$38.8m

Dimerix

ASX:DXB

AU$192.5m

Beroni Group

NSX:BTG

AU$75.9m

Noxopharm

ASX:NOX

AU$30.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Paradigm Biopharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.33
52 Week Hoogtepunt	AU$0.47
52 Week Laag	AU$0.17
Bèta	0.87
11 maand verandering	58.54%
3 maanden verandering	38.30%
1 Jaar Verandering	-14.47%
33 jaar verandering	-85.36%
5 jaar verandering	-91.65%
Verandering sinds IPO	-8.45%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	PAR	AU Biotechs	AU Markt
7D	34.0%	-0.3%	0.9%
1Y	-14.5%	11.0%	18.4%

Rendement versus industrie: PAR presteerde slechter dan de Australian Biotechs -sector, die het afgelopen jaar een rendement van 11 % opleverde.

Rendement versus markt: PAR presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 18.4 % opleverde.

Prijsvolatiliteit

Is PAR's price volatile compared to industry and market?
PAR volatility
PAR Average Weekly Movement	15.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.2%

Stabiele aandelenkoers: De aandelenkoers van PAR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 15% ) van PAR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Australian.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	n/a	Paul Rennie	www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited houdt zich bezig met onderzoek naar en ontwikkeling van therapeutische producten voor menselijk gebruik in Australië. De belangrijkste kandidaat is Zilosul, een injecteerbaar pentosan polysulfaatnatriummedicijn voor de behandeling van osteoartritis, mucopolysaccharidosis, rossriviervirus, chikungunya-virus, chronisch hartfalen, allergische luchtwegaandoeningen en acute ademnoodsyndroomaandoeningen. Het bedrijf werd opgericht in 2014 en heeft zijn hoofdkantoor in Melbourne, Australië.

Paradigm Biopharmaceuticals Limited Samenvatting

Hoe verhouden de winst en inkomsten van Paradigm Biopharmaceuticals zich tot de beurswaarde?
PAR fundamentele statistieken
Marktkapitalisatie	AU$113.87m
Inkomsten(TTM)	-AU$58.65m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.9x

Koers/Winstverhouding

Is PAR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PAR resultatenrekening (TTM)
Inkomsten	AU$0
Kosten van inkomsten	AU$8.99k
Brutowinst	-AU$8.99k
Overige uitgaven	AU$58.64m
Inkomsten	-AU$58.65m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.17
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde PAR op de lange termijn?

Bekijk historische prestaties en vergelijking

PAR Overzicht aandelen

Risicoanalyse

Paradigm Biopharmaceuticals Limited Concurrenten

ASX:CYP

AU$38.8m

ASX:DXB

AU$192.5m

NSX:BTG

AU$75.9m

ASX:NOX

AU$30.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New major risk - Financial position

New minor risk - Profitability

Recent updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New major risk - Financial position

New minor risk - Profitability

Insufficient new directors

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.21 loss per share (vs AU$0.17 loss in FY 2022)

Founder recently bought AU$76k worth of stock

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Forecast to breakeven in 2024

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

New 90-day low: AU$2.30

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme

New 90-day low: AU$2.38

New 90-day low: AU$2.42

Paradigm Biopharmaceuticals Ltd Receives the Written Response from the Type-C meeting with the US Food and Drug Administration (FDA) regarding Zilosul® for the Treatment of Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces Resignation of Chris Fullerton as Non- Executive Director

Paradigm Biopharmaceuticals Limited Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating PPS in Mucopulysaccharidoses Type-1

Paradigm Biopharmaceuticals Limited Adds Senior Executives to its Team

Paradigm Biopharmaceuticals Ltd Clear Path Towards Zilosul's Oa Phase 3 Clinical Trial and Product Registration in Europe

Paradigm Biopharmaceuticals Ltd Reports Additional Data on Patients Who Received Zilosul® Under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS)

New 90-day low: AU$2.32

New 90-day low - AU$2.54